SCHEMBL10026482

SCHEMBL10026482

CC(C)Oc1cc(O)c2ccc(Cl)c(Cl)c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.39
CYP3A4 P08684 1/20 0.32
MAPK1 P28482 1/20 0.32
PPARG P37231 1/20 0.31
TSHR P16473 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
HPGD P15428 1/20 0.30
MEN1 O00255 1/20 0.30
CYP1A2 P05177 1/20 0.30
POLB P06746 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
ATM Q13315 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10026485 0.87 MAPT (0.41) MAPTPPARGKDM4EALDH1A1LMNA
SCHEMBL6878521 0.85 MAPT (0.36) MAPTKDM4EALDH1A1GAAMEN1
SCHEMBL6876345 0.81 TSHR (0.38) MAPTMAPK1TSHRKDM4EALDH1A1
SCHEMBL12629381 0.79 MAPT (0.43) MAPTTSHRMEN1CYP1A2POLB
SCHEMBL6877317 0.77 MAPT (0.39) MAPTTSHRMEN1CYP1A2POLB
SCHEMBL10026484 0.75 MAPT (0.41) MAPTMEN1CYP1A2POLBCYP2D6
SCHEMBL6877766 0.75 MAPT (0.41) MAPTMEN1CYP1A2POLBCYP2D6
SCHEMBL6875131 0.74 MAPT (0.40) MAPTCYP3A4MAPK1TSHRKDM4E
SCHEMBL6876080 0.74 KDM4E (0.42) MAPTCYP3A4TSHRKDM4EALDH1A1
SCHEMBL11392979 0.74 CYP3A4 (0.40) MAPTCYP3A4MAPK1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077737-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-29 US disclosed
US-20120077737-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-29 US disclosed
WO-2011063501-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077737-A1 HEPATITIS C INHIBITOR COMPOUNDS CTSC, HCCS, CTSZ MAPT 4636/4885CYP3A4 793/4885MAPK1 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.